|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500096854 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-07 16:19:02 |
|
注册时间: Date of Registration: |
2025-02-07 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
经注药型气管导管表面麻醉对颅内动脉瘤介入手术患者全麻苏醒期应激反应的影响:随机安慰剂对照双盲研究 |
|
Public title: |
Effect of topical anesthesia with endotracheal tube for drug injection on stress response during emergence from general anesthesia in patients undergoing intracranial aneurysm interventional surgery: a randomized placebo-controlled double-blind study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
经注药型气管导管表面麻醉对颅内动脉瘤介入手术患者全麻苏醒期应激反应的影响:随机安慰剂对照双盲研究 |
|
Scientific title: |
Effect of topical anesthesia with endotracheal tube for drug injection on stress response during emergence from general anesthesia in patients undergoing intracranial aneurysm interventional surgery: a randomized placebo-controlled double-blind study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陶飞 |
研究负责人: |
顾卫东 |
|
Applicant: |
Tao Fei |
Study leader: |
Gu Weidong |
|
申请注册联系人电话: Applicant telephone: |
+86 151 9679 1776 |
研究负责人电话: Study leader's telephone: |
+86 189 1816 9021 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2480028389@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
mcwgwd@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区延安西路221号7号楼6楼麻醉科 |
研究负责人通讯地址: |
上海市静安区延安西路221号7号楼6楼麻醉科 |
|
Applicant address: |
Department of Anesthesiology, 6th Floor, Building 7, 221 Yan'an Road West, Jing'an District, Shanghai |
Study leader's address: |
Department of Anesthesiology, 6th Floor, Building 7, 221 Yan'an Road West, Jing'an District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属华东医院 |
||
|
Applicant's institution: |
Huadong Hospital affiliated to Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属华东医院 |
||
|
Affiliation of the Leader: |
Huadong Hospital affiliated to Fudan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
20250002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属华东医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Huadong Hospital Affiliated to Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-01-08 00:00:00 |
||
|
伦理委员会联系人: |
沙颖豪 |
||
|
Contact Name of the ethic committee: |
Sha Yinghao |
||
|
伦理委员会联系地址: |
上海市静安区延安西路168号 |
||
|
Contact Address of the ethic committee: |
168 Yan'an Road West, Jing'an District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6248 3180 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属华东医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Huadong Hospital affiliated to Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市静安区延安西路221号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
221 Yan'an Road West, Jing'an District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
麻醉医师围术期管理护佑专项基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Anesthesiologists’ Perioperative Management and Care Special Fund |
||||||||||||||||||||||
|
Target disease: |
Intracranial aneurysms |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评估经注药型气管导管注射1%利多卡因对颅内动脉瘤介入手术患者全麻苏醒期应激反应的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effect of intratracheal catheter injection of 1% lidocaine on stress response during recovery from general anesthesia in patients undergoing interventional surgery for intracranial aneurysms. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 气管插管全麻下行颅内动脉瘤介入手术的患者; 2. ASA I-II级; 3. 年龄≥18岁; 4. 行单腔普通气管导管置入; 5. Mallampatti分级I-Ⅲ级; 6. BMI 18-28 kg/m^2。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients with intracranial aneurysms undergoing interventional surgery under general anesthesia with endotracheal intubation; 2. ASA grade I-II; 3. Age >=18 years old; 4. Single lumen common endotracheal tube was placed; 5. Mallampatti grade I-III; 6. BMI 18-28 kg/m^2. |
||||||||||||||||||||||
|
排除标准: |
1. 预计插管困难或术后预计不拔管; 2. 术前存沟通障碍 ; 3. 慢性咳嗽; 4. 服用ACEI或镇咳类药物 ; 5. 酰胺类局麻药过敏史; 6. 严重肝肾功能障碍 / 心血管疾病 / 神经系统疾病; 7. 哮喘史或气道高敏状态; 8. 近期患有呼吸道感染 / 感冒; 9. 高反流误吸风险(妊娠/肥胖/消化道梗阻/急诊饱胃/食管梗阻/食管气管瘘/高颅内压/恶心呕吐/贲门松弛/病情危重等)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Difficult intubation is expected or no extubation is expected after operation 2. preoperative communication disorders 3. Chronic cough 4. ACEI or antitussive drugs 5. History of allergy to amide local anesthetics 6. severe liver and kidney dysfunction/cardiovascular disease/nervous system disease 7. History of asthma or airway hypersensitivity 8. Recent respiratory infection/cold 9. High risk of reflux aspiration (pregnancy/obesity/gastrointestinal obstruction/emergency satiety/esophageal obstruction/esophagotracheal fistula/high intracranial pressure/nausea and vomiting/cardia relaxation/critical condition, etc.). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-10 00:00:00至 To 2025-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-01-10 00:00:00 至 To 2025-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机序列的产生由不相关的第三方统计学专家负责完成,将符合纳入和排除标准的研究对象按照1:1随机分配至试验组和对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The random sequence was generated by an unrelated third party statistician. The subjects who met the inclusion and exclusion criteria were randomly assigned to the experimental group and the control group in a 1:1 ratio. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
手术当天由一名不参与临床研究的麻醉护士配置药液,并将药液放入相应随机序列编号的信封中,交给麻醉医生。该麻醉医生不清楚分组情况,负责评估的苏醒室麻醉医生及患者本人也不清楚分组情况。 |
|
Blinding: |
On the day of surgery, a nurse anesthetist who was not involved in the clinical study dispensed the solution and placed it in the corresponding random sequence number envelope and handed it to the anesthesiologist. The anesthesiologist, the assessed PACU anesthesiologist, and the patient were unaware of the group assignments. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
学术期刊(预计2025年5月完成发表) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Academic journal(Publication is expected to be completed by May 2025) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
临床试验机构应当保存临床试验资料至临床试验结束后 10 年;申办者应当保存临床试验资料至无该医疗器械使用时。这些数据交由有资质的数据管理方按照与申办方协商制定的《数据管理计划》进行数据管理和清理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All raw data should be preserved at their respective clinical trial sites for up to 10 years and by the study sponsor until such medical device is no longer in use. Data will be processed and managed by a qualified third-party data management provider in accordance with Data Management Plan agreed upon by both parties. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |